-
Microbicide research suffered a setback earlier this year when a phase III clinical trial studying cellulose sulfate to block HIV infection was stopped prematurely because there appeared to be a higher rate of HIV infections among the study group than the control group.
-
The latest microbicide clinical trials will use antiretroviral therapy (ART), which holds both promise and more challenges for investigators.
-
Prophylaxis against pcp remains the single most cost-effective intervention in HIV+ patients at risk. But treatment has, in some ways, become a moving target in some patients, as their CD4 count rises and falls with newer HIV therapies, medication side effects, and variable compliance.
-
More than two million people living with HIV/AIDS in low and middle income countries now have access to antiretroviral therapy (ART), according to a recent report.
-
'Lights camera:' Bill calls for videotaped surgeries; Medical researchers not as unbiased as they think
-
A project to assess the impact on community health centers of recent Deficit Reduction Act changes that require Medicaid applicants and recipients to document their citizenship, legal U.S. residence, and personal identity has found significant adverse effects in terms of coverage disruptions and loss of Medicaid income.
-
-
With an ever-expanding range of hazardous drugs, hospitals must identify employees at risk and conduct medical surveillance at least annually, according to the National Institute for Occupational Safety and Health (NIOSH).
-
Faced with a shortage of hospital beds that extends throughout the state of Washington, St. Joseph's Medical Center in Tacoma has embarked on an "express discharge" initiative, which alerts the treatment team a day in advance when physicians anticipate the patient is almost ready for discharge.
-
The Centers for Medicare & Medicaid Services (CMS) has not yet issued its final rule for fiscal year 2008, but it'sï